GAIN THERAPEUTICS, INC Investing Cash Flow
GAIN THERAPEUTICS, INC (GANX) reported Investing Cash Flow of $4.98 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-03-26
- GAIN THERAPEUTICS, INC net cash provided by (used in) investing activities for the quarter ending 2024-12-31 was -$43.45K, a 101.38% decline year-over-year.
- GAIN THERAPEUTICS, INC net cash provided by (used in) investing activities for the quarter ending 2024-09-30 was -$1.00, a 100.00% decline year-over-year.
- GAIN THERAPEUTICS, INC net cash provided by (used in) investing activities for the quarter ending 2024-06-30 was $2.00M, a 34.25% decline year-over-year.
- GAIN THERAPEUTICS, INC net cash provided by (used in) investing activities for the quarter ending 2024-03-31 was $3.02M, a 43.27% increase year-over-year.
- GAIN THERAPEUTICS, INC net cash provided by (used in) investing activities for fiscal 2024 was $4.98M, a 51.31% decline from fiscal 2023.
- GAIN THERAPEUTICS, INC net cash provided by (used in) investing activities for fiscal 2023 was $10.22M.
- GAIN THERAPEUTICS, INC net cash provided by (used in) investing activities for fiscal 2022 was -$14.77M.
- GAIN THERAPEUTICS, INC net cash provided by (used in) investing activities for fiscal 2021 was -$94.21K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$43.45K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$43.45K derived: sum of 2 quarters · filed 2026-03-26 | $1.96M derived: sum of 3 quarters · filed 2026-03-26 | $4.98M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.00M derived: sum of 2 quarters · filed 2025-11-12 | $5.02M 10-Q · filed 2025-11-12 | $8.16M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $5.02M 10-Q · filed 2025-08-12 | $8.16M derived: sum of 3 quarters · filed 2025-08-12 | $10.09M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $3.02M 10-Q · filed 2025-05-14 | $6.16M derived: sum of 2 quarters · filed 2025-05-14 | $8.09M derived: sum of 3 quarters · filed 2025-05-14 | $11.13M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $5.07M derived: sum of 2 quarters · filed 2025-03-27 | $8.12M derived: sum of 3 quarters · filed 2025-03-27 | $10.22M 10-K · filed 2025-03-27 |
| 2023-09-30 | $1.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $4.97M derived: sum of 2 quarters · filed 2024-11-14 | $7.08M 10-Q · filed 2024-11-14 | $7.21M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $3.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.15M 10-Q · filed 2024-08-08 | $5.29M derived: sum of 3 quarters · filed 2024-08-08 | $5.27M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.11M 10-Q · filed 2024-05-14 | $2.24M derived: sum of 2 quarters · filed 2024-05-14 | $2.23M derived: sum of 3 quarters · filed 2024-05-14 | -$12.66M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $133.83K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $122.42K derived: sum of 2 quarters · filed 2024-03-26 | -$14.77M derived: sum of 3 quarters · filed 2024-03-26 | -$14.77M 10-K · filed 2024-03-26 |
| 2022-09-30 | -$11.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$14.90M derived: sum of 2 quarters · filed 2023-11-14 | -$14.91M 10-Q · filed 2023-11-14 | -$14.92M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$14.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$14.90M 10-Q · filed 2023-08-10 | -$14.91M derived: sum of 3 quarters · filed 2023-08-10 | -$14.94M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$7.83K 10-Q · filed 2023-05-12 | -$18.92K derived: sum of 2 quarters · filed 2023-05-12 | -$51.05K derived: sum of 3 quarters · filed 2023-05-12 | -$73.55K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$11.10K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$43.22K derived: sum of 2 quarters · filed 2023-03-23 | -$65.72K derived: sum of 3 quarters · filed 2023-03-23 | -$94.21K 10-K · filed 2023-03-23 |
| 2021-09-30 | -$32.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$54.63K derived: sum of 2 quarters · filed 2022-11-10 | -$83.11K 10-Q · filed 2022-11-10 | -$97.67K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$22.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$50.99K 10-Q · filed 2022-08-08 | -$65.54K derived: sum of 3 quarters · filed 2022-08-08 | -$66.96K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$28.49K 10-Q · filed 2022-05-16 | -$43.04K derived: sum of 2 quarters · filed 2022-05-16 | -$44.45K derived: sum of 3 quarters · filed 2022-05-16 | -$44.42K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$14.55K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | -$15.97K derived: sum of 2 quarters · filed 2022-03-25 | -$15.93K derived: sum of 3 quarters · filed 2022-03-25 | -$20.83K 10-K · filed 2022-03-25 |
| 2020-09-30 | -$1.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$1.38K derived: sum of 2 quarters · filed 2021-11-12 | -$6.28K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $38.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$4.86K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$4.90K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |